NEXR Technologies SE

  • WKN: A1K03W
  • ISIN: DE000A1K03W5
  • Land: Deutschland

Nachricht vom 06.10.2021 | 14:39

DGAP-DD: NEXR Technologies SE english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
06.10.2021 / 14:39
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: Hevella Capital GmbH & Co. KGaA

2. Reason for the notification

a) Position / status
Person closely associated with:
Title:
First name: Rolf
Last name(s): Elgeti
Position: Chairman of the Board of Directors of NEXR Technologies SE

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
NEXR Technologies SE

b) LEI
5299008Y94QHNMRK6U07 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Financial instrument linked to a share or a debt instrument
Description: Subscription right ISIN DE000A3E5EQ4

b) Nature of the transaction
Granting of 2,349,747 subscription rights as part of a capital increase with subscription rights.

c) Price(s) and volume(s)
Price(s) Volume(s)
0 EUR 0 EUR

d) Aggregated information
Price Aggregated volume
0 EUR 0 EUR

e) Date of the transaction
2021-10-04; UTC+2

f) Place of the transaction
Outside a trading venue



06.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021